James C. Arseneau

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

Fadlo R. Khuri, John Nemunaitis, Ian Ganly et al. · Nature Medicine · 2000 · 1.1K citations

Medicine, Oncology, Chemotherapy +8

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

Nasser H. Hanna, Marcus A. Neubauer, Constantin T. Yiannoutsos et al. · Journal of Clinical Oncology · 2008 · 496 citations

Medicine, Oncology, Radiation Oncology +15

Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

John Nemunaitis, Fadlo R. Khuri, Ian Ganly et al. · Journal of Clinical Oncology · 2001 · 474 citations · Full text

Life Sciences, Immunology, Oncology +17

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

John Nemunaitis, Ian Ganly, Fadlo R. Khuri et al. · PubMed · 2000 · 407 citations

Medicine, Cancer Biology, Oncology +16

Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease

James C. Arseneau, Robert W. Sponzo, David L. Levin et al. · New England Journal of Medicine · 1972 · 355 citations

Medicine, Oncology, Chemotherapy +13